Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Bolsters Warning On Phenergan Labeling At Urging Of Plaintiff's Attorney

This article was originally published in The Pink Sheet Daily

Executive Summary

Counsel for plaintiff in Wyeth v. Levine asked FDA to review the drug labeling after the Supreme Court's ruling in the case; the agency concluded the risk of severe tissue injury should be highlighted.

You may also be interested in...



Wyeth Lawyer On Lessons Of Levine v. Wyeth: Look For Patterns of Risk, Actively Manage The Labeling

FDA's recent requirement for stronger labeling of Phenergan (promethazine) reinforces the message from the Supreme Court in Levine v. Wyeth that finding a pattern of risk warrants label revisions, according to Wyeth's Chief Regulatory Counsel for Pharmaceuticals Geoffrey Levitt

Wyeth Lawyer On Lessons Of Levine v. Wyeth: Look For Patterns of Risk, Actively Manage The Labeling

FDA's recent requirement for stronger labeling of Phenergan (promethazine) reinforces the message from the Supreme Court in Levine v. Wyeth that finding a pattern of risk warrants label revisions, according to Wyeth's Chief Regulatory Counsel for Pharmaceuticals Geoffrey Levitt

Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk

While the Supreme Court's landmark ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from product liability lawsuits, it will not trigger any sea change in litigation. Instead, the opinion seems likely to maintain the status quo and restrict the situations in which companies can claim they provided adequate warning of a drug's risks

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel